FDA recalls 2.2 million at-home coronavirus tests due to false positives

The FDA announced this week that the recall of more than 2.2 million at-home COVID-19 tests by digital diagnostics firm Ellume is being classified as a class 1 recall, which is the most serious type due to the potential for "serious adverse health consequences or death."

Ellume's at-home test detects proteins from the SARS-CoV-2 virus through a less invasive nasal swab than the one that health providers normally use. 

The recall is due to a "manufacturing issue" that was first identified by the company last month and could lead to a false-positive result. 

The FDA...